Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959812 · ClinicalTrials.gov registry record · Phase 1
Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04959812 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 46 participants.
The verdict
NCT04959812, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.
Interventions
- OTHER Placebo
- DRUG Sufentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959812
The ClinicalTrials.gov registry entry for NCT04959812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04959812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04959812 about?
NCT04959812 is a clinical study titled "Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil". This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.
What is the current status of trial NCT04959812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-03-01. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT04959812?
The interventions under investigation include: Placebo (OTHER), Sufentanil (DRUG).
Who is sponsoring clinical trial NCT04959812?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.